Background: Dengue fever (DF), one of the main emerging virus diseases, also increases in German travellers, due to the increasing number of travellers to tropical regions. Methods: We determined antibodies against DF virus in a group (n = 149) of long-distance travellers in order to evaluate the risk of acquiring DF. Serum samples were collected at the travel vaccination centre in Frankfurt/Main and DF seroprevalence in serum samples was determined using different antibody assays with particular attention to flavivirus cross-reactivity. So, antibodies against tick-borne encephalitis and previous flavivirus vaccination of the travellers were checked. Results: Depending on the test system, 8.7–19.5% of the screened travellers were found to be DF virus IgG antibody positive, significantly more than in previous investigations. Remarkably, younger adults and women are more often affected. Conclusions: These data imply that the risk for travellers to acquire DF has been underestimated. Nevertheless, dengue haemorrhagic fever and dengue shock syndrome are still rare in travellers, but those with a history of dengue should be advised to protect themselves well from mosquitoes when travelling to endemic areas.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.